Multiple cutting-edge targets have welcomed data catalysts, with strong certainty in drug viability, suggesting to focus on domestic companies that are targeting new Innovative Drugs for lipid reduction.
According to the Zhitong Finance APP, Huafu Securities has released a Research Report stating that the burden of ASCVD is increasingly heavy in China, with approximately 0.1 billion people experiencing hyperlipidemia, but the treatment rate for dyslipidemia is low. Traditional statin drugs among existing medications have certain limitations, and there is a significant unmet demand in the lipid-lowering industry. In terms of drug development, multiple cutting-edge targets are welcomed by data catalysis, with strong drug development certainty. The development of new targets is expected to address the treatment needs for reducing various lipid Indicators, achieving greater reductions in LDL-C, and treating rare diseases associated with lipid abnormalities. It is recommended to position domestic companies focused on innovative drugs with new targets for lipid-lowering.
The main views of Huafu Securities are as follows:
China has a large population of hyperlipidemia patients, and the rate of achieving lipid targets is relatively low.
According to data from the Silver Hua Kangling Health Management WeChat public account's "Report on Nutrition and Chronic Disease Status of Chinese Residents 2020", there are 0.2 billion people with lipid abnormalities in China, with approximately 0.1 billion people experiencing hyperlipidemia, which may cause vascular embolism. Cardiovascular diseases (CVD), mainly characterized by Atherosclerotic Cardiovascular Disease (ASCVD), are the leading cause of death among urban and rural residents in China, accounting for over 40% of mortality causes.
It has been confirmed that low-density lipoprotein cholesterol (LDL-C) is a pathogenic risk factor for ASCVD. ASCVD is the most significant chronic non-communicable disease threatening global human health, especially as the disease burden increases in China. Among ultra-high-risk patients, the long-term rate of achieving LDL-C targets is only 30.1%.
There is a significant unmet demand in the lipid-lowering industry.
The treatment rate for lipid disorders in patients in China is currently low, and the existing traditional statin drugs have certain limitations, such as some patients experiencing statin intolerance and insufficient LDL-C efficacy. Additionally, the long-term adherence to PCSK9 monoclonal antibodies is not ideal. There is a lack of specific targeted drugs for Lp(a), which is an independent risk factor for reducing cardiovascular events. There is significant unmet demand in the lipid-lowering field. The current direction for the development of new lipid-lowering drugs includes lower lipid targets, earlier lipid-lowering interventions, and long-term compliance.
Multiple cutting-edge targets are seeing data catalyze their development, with strong drug-likeness.
Currently, the PCSK9 target is maturing and gradually evolving towards more advanced technological routes (such as small nucleic acid drugs). Other lipid-lowering innovative targets like CETP, Lp(a), APOC3, and ANGPTL3 are also under hot development. The development of these new targets is expected to address the treatment demands for reducing different lipid indicators, achieving greater reductions in LDL-C, and treating rare lipid disorders.
Suggested attention: Domestic companies focusing on innovative drug new targets for lipid lowering include Jiangsu Hengrui Pharmaceuticals (600276.SH), CSPC PHARMA (01093), AKESO (09926), INNOVENT BIO (01801), Shenzhen Salubris Pharmaceuticals (002294.SZ), and Zhejiang Jingxin Pharmaceutical (002020.SZ).
Risk warning: Development progress may not meet expectations; product sales may not meet expectations; centralized procurement policies may not meet expectations.
Today, after hitting the high near 24,000 in the early session and entering bearish positions, the index fell sharply by nearly over 600 points, immediately recouping yesterday's losses significantly.
Moreover, today it broke the new high again, reaching a maximum of 24,076, but by the end of the market, it fell back by about 70 points, producing a bearish candle. The current trend has not yet been broken, but from the previous low until now, it has risen close to 6,000 points. It is believed that those with positions can continue to hold until there is a clear trend reversal for profit-taking. Those without positions can wait for a pullback to get in. Actually, it is hoped for a quick pullback, as it allows for entry and also provides a healthy breath.
Currently, the outlook remains the same as before. It is believed that even if there is a pullback, it shouldn't be too deep. However, if Futures fail to stabilize and close below 22,350, there may still be room for decline. The chance of Futures falling below 21,400 in the short term should be low, so it is considered that if a significant pullback occurs, it presents a good opportunity to incrementally go long. Recently, there has been a consistent approach to not hold positions overnight, only focusing on immediate trades, as there is no high chasing and no casual short selling.
Comment(1)
Reason For Report